NASDAQ$MLYS
Mineralys Therapeutics Inc · Q4 2026 earnings
Q4 2026 earnings · · After market close · Investor relations
Briefing
Mineralys Therapeutics reported Q4 2026 with no product revenue, net loss of $39.3M, and diluted loss per share of $0.47.
For the period ended 2026-03-31, Mineralys Therapeutics reported no product revenue. Clinical-stage biotech with no product revenue. Net loss $(39.3)M improved from $(42.2)M; loss per share $(0.47). Lorundrostat hypertension program in trials. R&D-stage; cash runway and Phase 2/3 readouts drive outlook.
- Clinical-stage biotech with no product revenue.
- Net loss $(39.3)M improved from $(42.2)M; loss per share $(0.47).
- Lorundrostat hypertension program in trials.
Headline financials
Revenue & EPS history
Mineralys Therapeutics · Revenue · Quarterly
$0
Forward guidance
R&D-stage; cash runway and Phase 2/3 readouts drive outlook.
Tailwinds
- Loss narrowed modestly YoY.
- Interest income $6M on cash.
- Focused single-asset hypertension story.
Headwinds
- No revenue.
- Clinical trial risk.
- Future dilution likely.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q4 2026
-1.0%
Avg return
Earnings day
-5.9%
Avg return
5 days after
+5.5%
Avg return
30 days after
53%
8 / 15 earnings
Positive
+10.0%
Q4 2024
Best reaction
-9.2%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -2.9% | -2.9% | -21.3% | |
| Q3 2025 | +5.9% | -8.2% | -19.0% | |
| Q2 2025 | +0.4% | +13.5% | +174.6% | |
| Q1 2025 | +2.6% | +4.8% | +6.1% | |
| Q4 2024 | +10.0% | +6.0% | +47.5% | |
| Q3 2024 | -4.7% | -18.2% | -7.8% | |
| Q1 2024 | -7.7% | -10.9% | -10.3% | |
| Q4 2023 | -4.1% | -4.1% | -15.7% | |
| Q3 2022 | +0.7% | -20.4% | -14.8% | |
| Q3 2023 | +0.7% | -20.4% | -14.8% | |
| Q2 2023 | +0.5% | -3.7% | -8.9% | |
| Q2 2022 | +0.5% | -3.7% | -8.9% | |
| Q1 2023 | -4.3% | -4.0% | -1.2% | |
| Q1 2022 | -4.3% | -4.0% | -1.2% | |
| Q4 2022 | -9.2% | -12.3% | -22.0% | |
| Q4 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro